nach oben

International Journal of Clinical Oncology

Erschienen in:

18.04.2022 | Original Article

Efficacy and safety of regorafenib in Japanese patients with advanced gastrointestinal stromal tumors

verfasst von: Ryugo Teranishi, Tsuyoshi Takahashi, Toshirou Nishida, Seiichi Hirota, Yukinori Kurokawa, Takuro Saito, Kazuyoshi Yamamoto, Kotaro Yamashita, Koji Tanaka, Tomoki Makino, Masaaki Motoori, Takeshi Omori, Kiyokazu Nakajima, Hidetoshi Eguchi, Yuichiro Doki

Erschienen in: International Journal of Clinical Oncology | Ausgabe 7/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Regorafenib is an oral multi-kinase inhibitor that has been established as third-line treatment for patients after the failure of imatinib and sunitinib. However, since clinical data of regorafenib in the Japanese population are still lacking, the management of regorafenib is mainly based on the clinical experience of each oncologist. The aim of this study was to evaluate the efficacy and safety of regorafenib in a Japanese population.

Methods

Thirty-three patients treated with regorafenib for metastatic and recurrent gastrointestinal stromal tumors were retrospectively enrolled. This study investigated the anti-tumor effect, including overall survival, progression-free survival, and safety, which was evaluated based on the incidence of adverse events.

Results

The median overall survival of patients treated with regorafenib was 23.8 months and the 1-year overall survival rate was 80.0%, the median progression-free survival was 7.1 months and the 1-year progression-free survival rate was 40.2%. The responses to regorafenib were partial response in 3 cases (9.1%), stable disease in 17 (51.5%), progressive disease in 10 (30.3%), and non-evaluable in 3 (9.1%). The disease control rate was 54.0%. Treatment-related adverse events were reported in all patients, with the most common being hand-foot syndrome (72.7%), followed by liver damage (36.4%) and diarrhea (27.3%), and six patients (20.0%) were discontinued due to adverse events.

Conclusion

This is the first report of Japanese patients with gastrointestinal stromal tumors treated with regorafenib. Regorafenib showed efficacy and a manageable safety profile in Japanese patients with advanced gastrointestinal stromal tumors, which was comparable with previous studies.

Nur mit Berechtigung zugänglich

DeMatteo RP, Lewis JJ, Leung D et al (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231:51–58PubMedPubMedCentralCrossRef

Steigen SE, Eide TJ (2006) Trends in incidence and survival of mesenchymal neoplasm of the digestive tract within a defined population of northern Norway. APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica 114:192–200PubMedCrossRef

Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 23:70–83PubMedCrossRef

Joensuu H (2008) Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 39:1411–1419PubMedCrossRef

Hirota S, Isozaki K, Moriyama Y et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science (New York, NY) 279:577–580CrossRef

Heinrich MC, Corless CL, Duensing A et al (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science (New York, NY) 299:708–710CrossRef

Heinrich MC, Corless CL, Demetri GD et al (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342–4349PubMedCrossRef

Demetri GD, von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472–480PubMedCrossRef

Verweij J, Casali PG, Zalcberg J et al (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364:1127–1134PubMedCrossRef

10.

Demetri GD, von Mehren M, Antonescu CR et al (2010) NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Cancer Netw JNCCN 8(Suppl 2):S1-41CrossRef

11.

Corless CL, Fletcher JA, Heinrich MC (2004) Biology of gastrointestinal stromal tumors. J Clin Oncol 22:3813–3825PubMedCrossRef

12.

Gramza AW, Corless CL, Heinrich MC (2009) Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors. Clin Cancer Res 15(24):7510–7518PubMedCrossRef

13.

Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329–1338PubMedCrossRef

14.

Heinrich MC, Maki RG, Corless CL et al (2008) Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 26:5352–5359PubMedPubMedCentralCrossRef

15.

Wilhelm SM, Dumas J, Adnane L et al (2011) Regorafenib (BAY 73–4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129:245–255PubMedCrossRef

16.

Demetri GD, Reichardt P, Kang YK et al (2013) Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:295–302PubMedCrossRef

17.

Nishida T, Hirota S, Yanagisawa A et al (2008) Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version. Int J Clin Oncol 13:416–430PubMedCrossRef

18.

Komatsu Y, Doi T, Sawaki A et al (2015) Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial. Int J Clin Oncol 20:905–912PubMedPubMedCentralCrossRef

19.

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRef

20.

Hu CH, Yeh CN, Chen JS et al (2020) Regorafenib treatment outcome for Taiwanese patients with metastatic gastrointestinal stromal tumors after failure of imatinib and sunitinib: a prospective, non-randomized, single-center study. Oncol Lett 20:2131–2142PubMedPubMedCentralCrossRef

21.

Kollàr A, Maruzzo M, Messiou C et al (2014) Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program. Clin Sarcoma Res 4:17PubMedPubMedCentralCrossRef

22.

Chamberlain F, Farag S, Williams-Sharkey C et al (2020) Toxicity management of regorafenib in patients with gastro-intestinal stromal tumour (GIST) in a tertiary cancer centre. Clin Sarcoma Res 10:1PubMedPubMedCentralCrossRef

23.

Schvartsman G, Wagner MJ, Amini B et al (2017) Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients. Sci Rep 7:9519PubMedPubMedCentralCrossRef

24.

Hashiguchi Y, Muro K, Saito Y et al (2020) Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol 25:1–42PubMedCrossRef

25.

Kudo M, Kawamura Y, Hasegawa K et al (2021) Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update. Liver Cancer 10:181–223PubMedPubMedCentralCrossRef

26.

Grothey A, Van Cutsem E, Sobrero A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303–312PubMedCrossRef

27.

Bruix J, Qin S, Merle P et al (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389:56–66PubMedCrossRef

28.

Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330–337

29.

Kinzler KW (1996) Vogelstein B. Lessons from hereditary colorectal cancer. Cell 87:159–170PubMedCrossRef

30.

El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557–2576PubMedCrossRef

31.

Nakagawa H, Shibata T (2013) Comprehensive genome sequencing of the liver cancer genome. Cancer Lett 340:234–240PubMedCrossRef

32.

Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34PubMedCrossRef

33.

Ueda T, Uemura H, Tomita Y et al (2013) Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial. Jpn J Clin Oncol 43(6):616–628PubMedPubMedCentralCrossRef

34.

Yeh CN, Chen MH, Chen YY et al (2017) A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17. Oncotarget 8:44121–44130PubMedPubMedCentralCrossRef

35.

Son MK, Ryu MH, Park JO et al (2017) Efficacy and safety of Regorafenib in Korean patients with advanced gastrointestinal stromal tumor after failure of imatinib and sunitinib: a multicenter study based on the management access program. Cancer Res Treat 49:350–357PubMedCrossRef

36.

Uetake H, Sugihara K, Muro K et al (2018) Clinical features of regorafenib-induced liver injury in Japanese patients from postmarketing experience. Clin Colorectal Cancer 17:e49–e58PubMedCrossRef

37.

Lee JH, Chung YH, Kim JA et al (2013) Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma. Cancer 119:136–142PubMedCrossRef

38.

Yoshino T, Komatsu Y, Yamada Y et al (2015) Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations. Investig New Drugs 33:740–750CrossRef

39.

Nannini M, Rizzo A, Nigro MC et al (2021) Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study. ESMO Open. 6:100222PubMedPubMedCentralCrossRef

40.

Bekaii-Saab TS, Ou FS, Ahn DH et al (2019) Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncol 20:1070–1082PubMedPubMedCentralCrossRef

41.

Argiles GMN, Valladares-Ayerbes M, de Prado JV et al (2019) Results of REARRANGE trial: a randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC). Ann Oncol 30 (Abstract O-026)

42.

Suzuki T, Sukawa Y, Imamura CK et al (2020) A phase II study of regorafenib with a lower starting dose in patients with metastatic colorectal cancer: exposure-toxicity analysis of unbound regorafenib and its active metabolites (RESET Trial). Clin Colorectal Cancer 19:13-21.e3PubMedCrossRef

43.

Heinrich MC, Corless CL, Blanke CD et al (2006) Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24:4764–4774PubMedCrossRef

44.

Liegl B, Kepten I, Le C et al (2008) Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 216:64–74PubMedPubMedCentralCrossRef

45.

George S, Wang Q, Heinrich MC et al (2012) Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol 30:2401–2407PubMedPubMedCentralCrossRef

46.

Murtaza M, Dawson SJ, Tsui DW et al (2013) Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497:108–112PubMedCrossRef

47.

Maier J, Lange T, Kerle I et al (2013) Detection of mutant free circulating tumor DNA in the plasma of patients with gastrointestinal stromal tumor harboring activating mutations of CKIT or PDGFRA. Clin Cancer Res 19:4854–4867PubMedCrossRef

48.

Nishida T, Doi T, Naito Y (2014) Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors. Expert Opin Pharmacother 15:1979–1989PubMedCrossRef

Titel: Efficacy and safety of regorafenib in Japanese patients with advanced gastrointestinal stromal tumors
verfasst von: Ryugo Teranishi
Tsuyoshi Takahashi
Toshirou Nishida
Seiichi Hirota
Yukinori Kurokawa
Takuro Saito
Kazuyoshi Yamamoto
Kotaro Yamashita
Koji Tanaka
Tomoki Makino
Masaaki Motoori
Takeshi Omori
Kiyokazu Nakajima
Hidetoshi Eguchi
Yuichiro Doki
Publikationsdatum: 18.04.2022
Verlag: Springer Nature Singapore
Erschienen in: International Journal of Clinical Oncology / Ausgabe 7/2022
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-022-02159-z

Springer Medizin

Efficacy and safety of regorafenib in Japanese patients with advanced gastrointestinal stromal tumors